ACRS vs BMY
ACRS: Aclaris Therapeutics is a clinical-stage biopharmaceutical firm developing a pipeline of novel treatments for immuno-inflammatory diseases through a strategy of internal R&D and strategic third-party partnerships. BMY: Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse modalities like biologics and CAR-T cell technology.
Side-by-side fundamentals
| Metric | ACRS | BMY | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.62 | $60.76 | |
| Market cap as of 2026-07-23 | $778M | $124.9B | |
| P/E as of 2026-07-23 | n/a | 20.91 | |
| PEG as of 2026-07-23 | n/a | -4.29 | |
| Net margin as of 2026-07-23 | -832.6% | +12.3% | BMY higher |
| Gross margin as of 2026-07-23 | +9.7% | +53.7% | BMY higher |
| Operating margin as of 2026-07-23 | -961.9% | +17.1% | BMY higher |
| ROE as of 2026-07-23 | -55.9% | +41.6% | BMY higher |
| ROA as of 2026-07-23 | -38.5% | +8.7% | BMY higher |
| Debt / equity as of 2026-07-23 | 0.00 | 2.22 | ACRS lower |
| Revenue growth (YoY) as of 2026-07-23 | -52.9% | +1.8% | BMY higher |
| Revenue CAGR (3y) SEC XBRL | -35.9% | +1.4% | BMY higher |
| Dividend yield as of 2026-07-23 | n/a | +4.1% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.78 | 0.23 | |
| 1-year return as of 2026-07-22 close | +247.0% | +26.5% | ACRS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.